OMB APPROVAL
	OMB Number: 3235-0080
	Expires: February 28, 2009
	Estimated average burden hours per response...1.00

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 000-49616

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address: 11588 Sorento Valley Road, Suite 17, San Diego, California 92121 Phone: 858-794-8889

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Common Stock, $0.001 par value per share

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

o 17 CFR 240.12d2-2(a)(1)

o 17 CFR 240.12d2-2(a)(2)

o 17 CFR 240.12d2-2(a)(3)

o 17 CFR 240.12d2-2(a)(4)

o Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.¹

þ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Halozyme Therapeutics, Inc., certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

May 9, 2007		By: /s/ David Ramsay		Secretary and Chief Financial Officer
Date		David Ramsay		Title

SEC 1654 (03-06)		Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.